Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a herbal tablet protect kidneys in diabetes?

NCT ID NCT01068041

Disease control Sponsor: PhytoHealth Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

This study tested a plant-based tablet called PH3 in 100 adults with diabetic nephropathy (kidney damage from diabetes). The goal was to see if PH3 can safely reduce protein in the urine, a sign of kidney stress, over 24 weeks. Researchers also looked at the best dose to use in future studies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PH3 (a plant-based tablet)
What this could lead to
If successful, PH3 could offer a new option to slow kidney damage in people with diabetes.
What could go wrong
This is an early Phase 2 trial with only 100 participants. It may not show clear benefit, and the optimal dose is still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

100 people

The number who actually took part.

Start date

Aug 2010

Finished

Sep 2015

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Males and Females between 18 and 70 years of age with type 1 or type 2 diabetes 2. Sitting blood pressure of \<=140/90 mm Hg 3. Serum creatinine \<=2.0 mg/dL 4. Urinary albumin: creatinine ratio between 30 mg/g to 1000 mg/g creatinine (of the first urine sample of the day) 5. Hemoglobin A1c \<=8% 6. Women of child-bearing potential must test negative in a pregnancy test and take contraception measures to prevent pregnancy and can not be breast-feeding 7. Voluntary written consent to participate in this study Exclusion Criteria: 1. History of major cardiovascular or cerebrovascular events within 6 months prior to screening 2. History of cancer 3. Receiving chronic nonsteroidal anti-inflammatory therapy 4. History of diabetic ketoacidosis 5. Has clinically significant deviation from normal physical examination findings that, in the principal investigator's judgment, may interfere with the study evaluation or affect subject safety 6. Has participated in other investigational trials within 28 days prior to study enrollment 7. Has taken herbal medical treatment as prescription medication and/or over-the- counter medication, within 28 days prior to study enrollment. 8. Has known allergy to the study drug

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic nephropathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic nephropathy

Contacts and locations

Locations

  • Taichung Veterans General Hospital

    Taichung, 407, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Tri-Service General Hospital

    Taipei, 114, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.